alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 801–825 of 911 studies · free to read · tagged Diagnosis (page 33 of 37) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

EEG microstate alterations in Parkinson’s disease dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Scientific Reports 2026-02-27

To investigate alterations in resting-state electroencephalogram (EEG) microstates across the cognitive spectrum of Parkinson's disease (PD) and to evaluate their utility as electrophysiological biomarkers of cognitive impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning-Based Alzheimer’s Disease Stage Diagnosis Utilizing Blood Gene Expression and Clinical Data: A Comparative Investigation

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Diagnostics 2025-01-17

Utilizing clinical data, the highest ROC AUC scores attained were 0.989, 0.927, and 0.907 for the identification of the CN, MCI, and dementia stages, respectively. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A comparison of cognitive and health assessment tools used in a dementia prevention and risk management program for urban-dwelling older aboriginal Australians (DAMPAA)

✓ Peer-reviewed alzhub usefulness score 36 out of 100. SSM - Mental Health 2025-04-29

There were weak or no correlations between the KICA-Cog and other cognitive assessment tools. 5 key findings →

Participants: 49 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Discovering Hidden Links: Harnessing Similarity Network Fusion to Reveal Common Clusters in Healthy Aging, Mild Cognitive Impairment, and Dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

The current study provides evidence that more nuanced, data‐driven approaches can reveal commonalities in the etiology and underlying neurobiology of individuals across traditional categories of CU, MCI, or AD. 5 key findings →

Participants: 515 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Promoting Brain Health in the Context of Normal Aging and Mild Cognitive Impairment: A Tutorial

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American journal of speech-language pathology 2026-06-18

There are significant opportunities for speech-language pathologists (SLPs) to play important roles in the primary and secondary prevention of Alzheimer's disease and related dementias (ADRD) beyond current practices. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

198 A UNIQUE COMMUNITY POST-DIAGNOSTIC DEMENTIA SUPPORT SERVICE DELIVERED BY THE ADVANCED NURSE PRACTITIONER

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Age and Ageing 2022-10-25

Patient satisfaction outcomes range from 71 - 100% with service intervention outcomes favourably indicating the direct impact of the service, which are unmeasurable to the older adult living with dementia, and include increases in: (i) Confidence - 90%; (ii) Mood - 50% and (iii) open to talking through difficulties encountered - 87%. 3 key findings →

Participants: 67,744 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Investigating dementia patterns by machine learning and graph-based marker analysis for multiclass dementia diagnosis

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Discover Computing 2026-05-18

Dementia is a debilitating disease that leads to a gradual loss of memory and other cognitive abilities and tends to develop in people over 60 years of age. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Improving Early Detection of Dementia: Extra Trees-Based Classification Model Using Inter-Relation-Based Features and K-Means Synthetic Minority Oversampling Technique

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Big Data and Cognitive Computing 2025-05-30

The early detection of dementia, a condition affecting both individuals and society, is essential for its effective management. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Leveraging Artificial Intelligence in the Diagnosis of Neurodegenerative Disorders (Alzheimer's and Dementia) and in Managing Medication Schedules"

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Damanhour Journal of Intelligent Systems and Informatics 2025-06-01

The Alzheimer's disease (AD) is recognized as one of the most common neurodegenerative causes of dementia worldwide, having been characterized by progressive cognitive decline for the most part. 2 key findings →

Participants: 461 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

‘Machine Learning’ multiclassification for stage diagnosis of Alzheimer’s disease utilizing augmented blood gene expression and feature fusion

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Discover Applied Sciences 2025-06-12

Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid biomarkers including tau protein and amyloid-beta 42 for early detection and differential diagnosis of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. International Journal of Advanced Biochemistry Research 2025-05-01

In 1906, Alois Alzheimer first described the neuropathological hallmarks of the disease that now bears his name. 2 key findings →

Participants: 62 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in individuals with dementia

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Frontiers in Neurology 2025-01-09

Our studies showed that DC and DRs in VD and AD groups were significantly lower than those in controls, while AC values were significantly higher. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of comprehensive nursing interventions on psychological well-being and treatment adherence in dementia patients

✓ Peer-reviewed alzhub usefulness score 35 out of 100. American Journal of Translational Research 2025-01-01

The observation group had significantly lower Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores than the control group (both P<0.001). 5 key findings →

Participants: 45 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

BDNF Val66Met Genotype, DNA Methylation, mRNA, and Protein Levels as Potential Blood-Based Biomarkers for Dementia and Cognitive Decline

✓ Peer-reviewed alzhub usefulness score 35 out of 100. International Journal of Molecular Sciences 2025-09-15

DNA methylation, mRNA and protein levels, and cognitive performance using the Mini-Mental State Examination (MMSE) and Clock Drawing Test (CDT). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Layer-Specific Colocalization of Microglia with Amyloid Plaques in the Middle Temporal Gyrus Predicts Cognitive Decline in Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Aging and Disease 2025-01-01

Alzheimer's disease (AD), the most common form of dementia, is marked by cognitive decline and amyloid-beta (Aβ) plaque deposition in the brain. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events